This company listing is no longer active
CTI BioPharma Dirección
Dirección controles de criterios 3/4
CTI BioPharma's CEO is Adam Craig, appointed in Mar 2017, they has a tenure of 6.25 years. Their total yearly compensation is $4.59M , comprised of 14.3% salary and 85.7% bonuses, including company stock and options. They directly owns 0.022% of the company’s shares, worth $267.56K. The average tenure of the management team and the board of directors is 6 years and 6.3 years respectively.
Información clave
Adam Craig
Chief Executive Officer (CEO)
US$4.6m
Compensación total
| Porcentaje del salario del CEO | 14.3% |
| Permanencia del CEO | 6.3yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 6yrs |
| Promedio de permanencia en la Junta Directiva | 6.3yrs |
Actualizaciones recientes de la dirección
Recent updates
CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch
Aug 17CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M
Aug 08CTI BioPharma: Approval Is Great, Now There's The Follow Through
Jul 19CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis
Jul 07CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
May 04CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating
Apr 11CTI BioPharma: A Speculative Buy Into The PDUFA Date
Mar 01CTI BioPharma: Long And Troubled History, Finally Approaching Approval
Dec 24FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA
Jun 01CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis
May 06CTI BioPharma: Accelerated Approval Pathway Looks Attractive
Dec 06Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$5m | US$657k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$112m |
| Jun 30 2022 | n/a | n/a | -US$121m |
| Mar 31 2022 | n/a | n/a | -US$118m |
| Dec 31 2021 | US$2m | US$633k | -US$98m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$63m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$3m | US$615k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$41m |
| Dec 31 2019 | US$2m | US$595k | -US$40m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$36m |
| Mar 31 2019 | n/a | n/a | -US$36m |
| Dec 31 2018 | US$3m | US$564k | -US$29m |
| Sep 30 2018 | n/a | n/a | -US$45m |
| Jun 30 2018 | n/a | n/a | -US$42m |
| Mar 31 2018 | n/a | n/a | -US$29m |
| Dec 31 2017 | US$6m | US$434k | -US$45m |
Compensación vs. Mercado: Adam's total compensation ($USD4.59M) is about average for companies of similar size in the US market ($USD3.55M).
Compensación vs. Ingresos: Adam's compensation has increased whilst the company is unprofitable.
CEO
Adam Craig (57 yo)
6.3yrs
Permanencia
US$4,592,646
Compensación
Dr. Adam R. Craig, M.D., Ph D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.3yrs | US$4.59m | 0.022% $ 267.6k | |
| Executive VP | 5.8yrs | US$1.47m | 0.013% $ 155.7k | |
| Executive VP & Chief Commercial Officer | no data | US$597.30k | 0.0027% $ 32.4k | |
| Senior Director of Investor Relations | 15yrs | sin datos | sin datos | |
| Senior Vice President Global Pharmaceutical Operations | no data | sin datos | sin datos | |
| Executive VP & Chief of Staff | no data | sin datos | sin datos | |
| Senior Vice President of Biometrics | 4.6yrs | sin datos | sin datos |
6.0yrs
Permanencia media
65yo
Promedio de edad
Equipo directivo experimentado: CTIC's management team is seasoned and experienced (6 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.3yrs | US$4.59m | 0.022% $ 267.6k | |
| Independent Director | 1.8yrs | US$301.12k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 9.9yrs | sin datos | sin datos | |
| Independent Chairman of the Board | 5.9yrs | US$352.12k | 0% $ 0 | |
| Independent Director | 6yrs | US$317.62k | 0% $ 0 | |
| Independent Director | 7.4yrs | US$303.62k | 0.033% $ 392.1k | |
| Independent Director | 11.8yrs | US$319.12k | 0.037% $ 442.1k | |
| Independent Director | 6.4yrs | US$330.62k | 0% $ 0 |
6.3yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: CTIC's board of directors are considered experienced (6.3 years average tenure).